ProofPilot, a NYC-based Software as a Service (SaaS) clinical trial research platform, raised over $12M in Series B financing.
The round was led by Mitsui & Co. (U.S.A.), Inc., with participation from Sopris Capital, LLC, First Trust Capital Partners, LLC, and Excelra, among others. As part of this raise, famed technology strategist and healthcare investor Esther Dyson, executive founder of Wellville, joins ProofPilot’s Board of Directors.
ProofPilot is revolutionizing the complex and arduous clinical trial market by offering a fully digitized platform with self-design study, trial process management, and remote source verification capabilities.
Founded in 2014 by Matthew Amsden, ProofPilot provides a software as a service (SaaS) product for anyone to design, launch, participate, and engage in research studies. The company provides:
- ProofPilot Rx for Life Science companies, and
- ProofPilot 365 for wellness interventions.
FinSMEs
04/04/2022